The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Open accessAbstract
The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (minimum inhibitory concentration 0.06 mug/ml). In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations. A single dose of R207910 inhibited mycobacterial growth for 1 week. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
52 Own result · 16 Own interpretation · 13 No basis given · 9 Sources not found · 1 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 was extensively distributed to tissues, including lungs and spleen (Fig. 3A, table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These average concentrations were greater than that achieving optimal activity in established infection in mice.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Low MICs were also found for other mycobacterial species, including Mycobacterium bovis, Mycobacterium kansasii and Mycobacterium ulcerans, as well as species naturally resistant to many other anti-TB agents and involved in opportunistic infections, such as Mycobacterium avium complex (MAC), Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium marinum (Table 1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 25 mg/kg, the activity of R207910 was significantly better than at 12.5 mg/kg (P = 0.005).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The bactericidal activity obtained by the RHZ combination after 2 months of therapy was matched by the combinations JHZ and RJZ after just 1 month of therapy.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, at 12.5 and 25 mg/kg, R207910 was significantly more active (P = 0.005) than 25 mg/kg isoniazid, a drug known for its strong, early bactericidal activity (Fig. 4A).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, the susceptibility of R207910-resistant M. tuberculosis strains remained unchanged to other anti-TB agents, including isoniazid, rifampin, streptomycin, amikacin, ethambutol and moxifloxacin.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To date, 20 molecules of the DARQ series have a minimum inhibitory concentration (MIC) below 0.5 µg/ml against M. tuberculosis H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data from a multiple-ascending-dose study have shown an increase (approximately by a factor of two) in AUC 0-24h from Day 1 to Day 14 of once-daily dosing at 50, 150 and 400 mg R207910, without substantial variation between subjects.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma levels associated with efficacy in mice are well tolerated in healthy human volunteers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
- Probably not a substantial claim. 3
- It may state two separate claims as one. 40
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The most active compound of the class, R207910, is a pure enantiomer with two chiral centers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No accumulation of R207910 was observed after five daily oral doses, indicating that slow redistribution from tissues contributed to the relatively long half-lives in plasma.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the second study, the good tolerability was maintained; only one subject withdrew from the study, because of a urinary tract infection (unrelated to R207910) after seven doses at 150 mg/day.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When added to the first-line triple TB therapy combination RHZ, 25 mg/kg R207910 (J) increased the drop in bacterial load in the lungs by 2 log 10 after 1 month of therapy compared with standard RHZ treatment regimen, and a further 1 log 10 drop after 2 months.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximum plasma concentrations (C max ) of 0.40-0.54µg/ml with a single 6.25 mg/kg/dose were achieved within 1 hour and 1.1-1.3µg/ml with a 25 mg/kg/dose within 2-4 hours.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of adverse events reported (supporting online text), were considered possibly related to the study medication-placebo (seven of 18 subjects) or R207910 (20 of 36 subjects).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plainconditionaln = 36- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The AUC showed a better correlation with the dose than C max , reflecting limitations in rate of absorption at higher dosing regimens, as confirmed in a single-dose pharmacokinetic study comparing C max and AUC after 6.25, 25 and 100 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This anti-mycobacterial-specific spectrum differs from that of isoniazid, which has very poor activity against MAC.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies using oral treatment of R207910 for 5 days per week for 4 weeks, starting the day after inoculation, the minimal dose of R207910 that prevented mortality in nonestablished infection was 1.5 mg/kg, and the minimal effective dose (MED) preventing gross lung lesions was 6.5 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposure of M. tuberculosis in log-phase growth to concentrations of R207910 at 10-fold MIC resulted in a 3 log 10 reduction in bacterial counts after 12 days, indicating that R207910 has bactericidal activity in vitro (table S2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Complementation studies have verified that the mutant atpE gene is responsible for resistance to R207910, implying that the atpE gene product is the target of R207910 in mycobacteria.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The range of MICs for the international reference strain M. tuberculosis H37Rv and six fully antibiotic susceptible isolates was 0.03-0.120µg/ml (Table 1), versus 0.500 µg/ml for rifampin and 0.120 µg/ml for isoniazid (results not shown).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 30 isolates of MDR-TB tested were susceptible to 0.100 µg/ml of R207910, and 17 (57%) were susceptible to 0.010 µg/ml of R207910 (Table 2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pharmacokinetic results from the single-ascending-dose study suggested that R207910 is well absorbed after single oral administration, and the peak concentration was reached at 5 hours (median value) post-dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 had much higher MICs for Corynebacterium and Helicobacter pylori (MIC 4.0 µg/ml), and especially for other organisms such as Gram-positive Nocardia, Streptococcus pneumoniae, Staphylococcus aureus and Enterococcus faecalis, or Gram-negative Escherichia coli and Haemophilus influenzae (table S1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Half-lives ranged from 43.7 to 64 hours in plasma and 28.1 to 92 hours in tissues (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of drugs included in the World Health Organization's firstline tuberculosis treatment regimen (rifampin, isoniazid and pyrazinamide) with R207910 accelerates bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The DARQ R207910 is a member of a new chemical class of anti-mycobacterial agents and has an MIC equal to or lower than that of reference compounds.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A single dose of 50 mg/kg R207910 in the non-established infection murine model of TB infection resulted in a bacteriostatic effect (0.5 log 10 drop in bacterial count in the lungs), which lasted for 8 days-a similar effect to that of rifapentine (10 mg/kg) (Fig. 3B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In established infection (treatment beginning 12-14 days after inoculation when bacterial load was 5.94 log 10 CFU), 25 mg/kg R207910 as monotherapy was at least as active as the triple combination therapy (rifampin [R] + isoniazid [H] + pyrazinamide [Z]), and more active than rifampin alone (Fig. 4B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (MIC 0.06 µg/ml).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean AUC 0-24h values were 7.91, 24 and 52 µg/hour/ml at steady state, corresponding to average concentrations of 0.33, 1.0 and 2.2 µg/ml across a dosing interval, with 50, 150 and 400 mg/day, respectively.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pharmacokinetics of R207910 were linear up to the highest dose tested (700 mg); both C max and AUC increased proportionally with the administered dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The two point mutations identified (D32V for M. smegmatis and A63P for M. tuberculosis) are both in the membrane-spanning domain region of the protein.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Areas under the concentration-time curve (AUCs) ranged from 5.0 to 5.9 µg/hour/ml with a 6.25 mg/kg/dose and 18.5 to 19.4 µg/hour/ml with a 25 mg/kg/dose (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“From selection experiments, the proportion of resistant mutants that emerged was 5 x 10 -7 and 2 x 10 -8 at four-fold MIC, and 5 x 10 -8 and 1 x 10 -8 at eight-fold MIC for M. tuberculosis and M. smegmatis, respectively (8).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [8] 8. Details of materials and methods and supporting online text are available as supporting material on Science Online.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of each of the three first-line drugs with R207910 resulted in a dramatic increase in potency, leading to complete culture conversion of the lungs in some animals after only 2 months of treatment.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 has potent early bactericidal activity in the nonestablished murine TB model, matching or exceeding that of isoniazid (Fig. 4A), which is consistent with in vitro observations pointing to a bactericidal activity.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, the bactericidal potency seen upon administration of a single dose of 100 mg/kg R207910 in vivo was similar to the effect seen upon continuous exposure of cultures to 0.6 µg/ml (or 10-fold the median MIC of the H37Rv strain) in vitro, giving a first indication of the pharmacodynamics of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the minimal bactericidal dose was very close to the MED, a finding confirming timedependent, rather than concentration-dependent, activity of R207910 in vitro.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data suggest that maintaining average plasma levels of 0.3 µg/ml/day across a dosing interval, which is achieved with a 100 mg/kg/week dose, is necessary to achieve optimal effect of monotherapy in mice infected with strain H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The killing effect was not increased by higher concentrations of the compound, suggesting the killing was time-dependent rather than concentration-dependent.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Although current first-line anti-TB drug regimens can achieve more than 99% efficacy, this is often reduced because of drug resistance (5).”
What the sources say
- Not matchedcites [5] 5. R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 163, 1055 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Not matched
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Structurally and mechanistically, DARQs are very different from both fluoroquinolones (including methoxyquinolones) and other quinoline classes, including mefloquine and its analogs 4-methylquinolines and 4quinolylhydrazones (9-13).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [9] 9. R. Jain, B. Vaitilingam, A. Nayyar, P. B. Palde, Bioorg. Med. Chem. Lett. 13, 1051 (2003).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [10] 10. C. M. Kunin, W. Y. Ellis, Antimicrob. Agents Chemother. 44, 848 (2000).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [11] 11. M. R. Barbachyn, S. J. Brickner, Patent (International Publication Number: WO 93/09103, International Publication Date: 13 May, 1993, International Application Number: PCT/US92/08267, International Filing Date: 1992).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [12] 12. L. Savini, L. Chiasserini, A. Gaeta, C. Pellerano, Bioorg. Med. Chem. 10, 2193 (2002). / www.sciencexpress.org /9 December 2004 / Page 4/ 10.1126/science.1106753
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [13] 13. S. Vangapandu, M. Jain, R. Jain, S. Kaur, P. P. Singh, Bioorg. Med. Chem. 12, 2501 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The long half-lives and consequently prolonged exposure are important factors determining the duration of activity in vivo and provide a rationale for less frequent dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A comparison of the sequences of ATP synthases of different bacteria and of eukaryotic ATP synthase provides a rationale for the specificity of the antibacterial spectrum and, to a lesser extent, the safety profile of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the distinct target of R207910 means that there is no crossresistance with existing anti-TB drugs, and our studies verified it is as effective against MDR strains as it is against fully antibiotic-susceptible strains.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Inhibition of ATP synthase function may lead to ATP depletion and imbalance in pH homeostasis, both contributing to decreased survival (15,16).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [15] 15. M. Rao, T. L. Streur, F. E. Aldwell, G. M. Cook, Microbiology 147, 1017 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [16] 16. G. Deckers-Hebestreit, K. Altendorf, Annu. Rev. Microbiol. 50, 791 (1996).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These are all attributes that are valuable for treatment of chronic infections and they may also be important for the development of simpler dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [17] 17. E. L. Nuermberger et al., Am. J. Respir. Crit. Care Med. 169, 421 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The paper relies on this without support.
No tuberculosis-specific drugs have been discovered in 40 years.
“Tuberculosis has been increasing significantly on a worldwide basis over the past decade, but no tuberculosisspecific drugs have been discovered in 40 years.”
The paper relies on this without support.
The murine TB model is predictive of human TB treatment outcomes.
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMC207 is bactericidal towards most species of mycobacteria (109), but is only bacteriostatic against M. avium (118) and M. smegmatis (Berney and Cook, unpublished data).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When mycobacterial cells (growing or non-growing) are treated with TMC207, time-dependent (not dose-dependent) killing is observed (109).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M. smegmatis was used for the initial compound screening that identified diarylquinoline (later named Bedaquiline) as a specific inhibitor of mycobacterial ATP synthase in 2005, which ended a 40-year dearth in anti-TB drug discovery (147).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen.”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Citations
Cites
Amino acid substitution matrices from protein blocks.
Henikoff, S., & Henikoff, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10915 · Cited by 6,218
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Comparing the Means of Several Groups
Godfrey, K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132305 · Cited by 740
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S. K., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 315
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
Siddiqi, S. H., Libonati, J. P., & Middlebrook, G. (1981) · Journal of Clinical Microbiology · doi:10.1128/jcm.13.5.908-912.1981 · Cited by 242
The Need for New Drugs against Tuberculosis
O'BRIEN, R. J., & NUNN, P. P. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2007122 · Cited by 221
THE F0F1-TYPE ATP SYNTHASES OF BACTERIA: Structure and Function of the F0 Complex
Deckers-Hebestreit, G., & Altendorf, K. (1996) · Annual Review of Microbiology · doi:10.1146/annurev.micro.50.1.791 · Cited by 195
Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG
Rao, M., Streur, T. L., Aldwell, F. E., & Cook, G. M. (2001) · Microbiology · doi:10.1099/00221287-147-4-1017 · Cited by 148
Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
Savini, L., Chiasserini, L., Gaeta, A., & Pellerano, C. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00071-8 · Cited by 134
Cited by
Sorted by citations
Items 1,601–1,700 of 2,159
Prithviraj, M., Shivangi, Freundlich, J. S., & Morita, Y. S. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110361 · Cited by 4
“To test the roles of ATP production more directly, we treated cells with bedaquiline, which is a tuberculosis drug initially identi fi ed through a screening of M. smegmatis (17) and inhibits mycobacterial ATPase (18).”
Alghamdi, S. A., Qusty, N. F., Maulana, A., Ajmal, M., Khan, M., Mahato, A. K., Verma, S., & Asif, M. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023603257 · Cited by 5
Hansen, M. F., Zulbeari, N., & Holm, R. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126103 · Cited by 4
Sorescu, J. M., González-Montalvo, M. A., Yuan, M., DePaolo-Boisvert, J., Ceapă, C. D., García‐Contreras, R., Flores-Herrera, Ó., Shea, M. E., Tuz, K., & Juárez, O. X. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2545785 · Cited by 5
“Moreover, bedaquiline has strong activity on the growth of a large number of mycobacteria species (Andries et al. 2005).”
Novel drugs and drug combinations for treating tuberculosis
Munang, M. L., O’Shea, M. K., & Dedicoat, M. J. (2014) · BMJ · doi:10.1136/bmj.g5948 · Cited by 4
F1Fo adenosine triphosphate (ATP) synthase is a potential drug target in non-communicable diseases
Singh, V. M. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08299-3 · Cited by 4
Rollo, R. F., Mori, G., Hill, T. A., Hillemann, D., Niemann, S., Homolka, S., Fairlie, D. P., & Blumenthal, A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00465-23 · Cited by 5
Ward, K. T., Williams, A. P. L., Blair, C. A., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00480 · Cited by 4
Therapy of Mycobacterium abscessus Infections in Solid Organ Transplant Patients
Osman, L., Lopez, C., Natori, Y., Anjan, S., Viotti, J. B., & Simkins, J. (2024) · Microorganisms · doi:10.3390/microorganisms12030596 · Cited by 4
“Bedaquiline is a diarylquinolone antibiotic that inhibits mycobacterial ATP synthase and is better known for its use in multidrug-resistant Mycobacterium tuberculosis infections as recommended by the World Health Organization [40,41].”
BackgroundSpectroscopic techniques for elucidating the mechanism of action of antibacterial agents
Bedair, H. M., Hamed, M., Magdy, G., & Mansour, F. R. (2024) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2024.2327519 · Cited by 5
Wang, L., Reheman, A., & Wan, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-65702-0 · Cited by 4
Sulfonamide Derivatives as Potent Antituberculosis Agents: A Literature Survey of the Past Decade
Rita, R., Kandari, A., Benjwal, S., et al. (2024) · ChemistrySelect · doi:10.1002/slct.202403396 · Cited by 4
Li, D., Zhang, X., Yao, Y., Sun, X. J., Sun, J., Ma, X., Yuan, K., Bai, G., Pang, X., Hua, R., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412653121 · Cited by 5
“Anti - TB drugs such as SQ109, ethambutol, and bedaquiline have been developed against MmpL3, arabinosyltransferases, and ATP synthase, which reside on the membrane ( 20 , 22 , 23 ).”
D’Oliveira, K. A., Souza, I. D. O., Glanzmann, N., Silva, A. D. D., Bruziguini, C. E. T., Ribeiro, M. A., Canales, C. S. C., Roque‐Borda, C. A., Pavan, F. R., & Cuin, A. (2025) · Journal of Coordination Chemistry · doi:10.1080/00958972.2024.2448518 · Cited by 4
Krah, A., Grover, V., Fong, T. C., et al. (2025) · Structure · doi:10.1016/j.str.2025.01.004 · Cited by 4
Nycz, J. E., Kolińska, J., Karaush‐Karmazin, N., et al. (2025) · Molecules · doi:10.3390/molecules30122659 · Cited by 4
“Quinoline and 1,10-phenanthroline derivatives represent highly versatile photoactive compounds that demonstrate distinct properties in coordination chemistry [1–5], medicinal chemistry [6–15], chemical engineering [16,17], electrochemistry [18,19], industrial chemistry [20,21], etc., [22,23].”
Emerging trends in tuberculosis therapy : A review
Agrawal, Y. K., Bhatt, H., Raval, H. G., Oza, P. M., Vaidya, H. B., Manna, K., Gogoi, P., & Highway, S. G. (2007) · Journal of Scientific & Industrial Research · Cited by 4
Chapter 1 Overview: Developments in DNA Sequencing
Mitchelson, K. R., Hawkes, D. B., Turakulov, R. I., & Men, A. E. (2007) · Perspectives in bioanalysis · doi:10.1016/s1871-0069(06)02001-5 · Cited by 4
Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)
Grosset, J. H. E., & Ammerman, N. C. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.811848 · Cited by 4
CHOUAID, C. (2005) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(05)85664-5 · Cited by 4
Judd, J., Boucher, N., Roey, E. V., Gray, T. A., & Derbyshire, K. M. (2017) · Journal of Bacteriology · doi:10.1128/jb.00410-17 · Cited by 4
“smegmatis an excellent model organism for genetic and biochemical studies 88 of mycobacteria (12-14).”
BackgroundTuberculosis - Present Medication and Therapeutic Prospects
Jelińska, A., Zając, M., Dadej, A., Tomczak, S., Geszke-Moritz, M., & Muszalska-Kolos, I. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181120100025 · Cited by 4
Molecular Basis of Drug Resistance in Mycobacteria
Katoch, V. M. (2019) · Springer eBooks · doi:10.1007/978-981-32-9449-3_1 · Cited by 4
Liu, P., Fan, S., Wang, B., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104054 · Cited by 4
Liu, F., Hu, J., Li, C., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104466 · Cited by 4
Ruiz‐Blanco, Y. B., Ávila‐Barrientos, L. P., Hernández‐García, E., Antunes, A., Agüero-Chapin, G., & García‐Hernández, E. (2020) · FEBS Letters · doi:10.1002/1873-3468.13988 · Cited by 4
Хохлов, А. Л., Mariandyshev, A., Shcherbakova, V. S., et al. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.12.200482 · Cited by 4
Unveiling p-quinone methide (QM) chemistry to synthesize bedaquiline (TMC 207) like architectures
Roy, D., Ali, K., & Panda, G. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130493 · Cited by 4
Carreto-Binaghi, L. E., González, Y., & Guzmán‐Beltrán, S. (2021) · NCT Neumología y Cirugía de Tórax · doi:10.35366/100997 · Cited by 6
“73,74 Se reportó que sólo 28 % de las cepas de M. tuberculosis identificadas como resistentes a bedaquilina tenían modificaciones en atpE .”
BackgroundBaksam, V. K., Nimmakayala, S., Pocha, V. R., et al. (2021) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmab134 · Cited by 4
Hussain, M. S., Vashist, A., Kumar, M., et al. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01743-2 · Cited by 4
Metabolic Perspectives on Persistence
Hartman, T. E., Wang, Z., Jansen, R. S., Gardete, S., & Rhee, K. Y. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch31 · Cited by 5
Implications of Mycobacterium tuberculosis Metabolic Adaptability on Drug Discovery and Development
Cardoso, N. C., Chibale, K., & Singh, V. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00627 · Cited by 4
Wallace, R. J., & Griffith, D. E. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00039-4 · Cited by 4
Regulatory Mechanisms and Environmental Adaptation of the F-ATPase Family
Iwamoto-Kihara, A. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00419 · Cited by 4
Calvet-Seral, J., Crespo-Yuste, E., Mathys, V., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05344-22 · Cited by 4
“tuberculosis, [14], [16] as a polymorphism conferring bedaquiline resistance.”
BackgroundSaini, R., & Dharavath, N. (2018) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-018-1410-3 · Cited by 4
Whole-Genome Sequencing in Relation to Resistance of Mycobacterium Tuberculosis
Dohál, M., Porvazník, I., Kusnir, P., et al. (2019) · Acta Medica Martiniana · doi:10.2478/acm-2019-0002 · Cited by 4
“bedaquilin drug target) and for patients with recurrent infections to determine whether it is a relapse (patient infected with the same strain) or reinfection (patient infected with a new strain) (51; 52).”
BackgroundAl-Ghafli, H., & Al‐Hajoj, S. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180731120544 · Cited by 4
Chan, C., Lai, C.-Y., & Wang, C. (2021) · Catalysts · doi:10.3390/catal11080877 · Cited by 4
Alajlani, M. M. (2022) · Molecules · doi:10.3390/molecules27030753 · Cited by 5
N-[(6-Bromo-2-methoxy-3-quinolyl)phenylmethyl]-2-morpholino-N-(1-phenylethyl)acetamide
Cai, Z., Xiong, G., Li, S.-R., et al. (2009) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536809027020 · Cited by 4
“Some quinoline derivatives can give effective and good quality drugs treating many cancers (Dalla Via et al., 2008), and also used as antifungals and antituberculostatics drugs (Andries et al., 2005; Mao et al., 2007; Gaurrand et al., 2006).”
BackgroundTargeting Bacterial Persistence to Develop Therapeutics Against Infectious Disease
Hong‐Geller, E., & Micheva‐Viteva, S. (2015) · InTech eBooks · doi:10.5772/59404 · Cited by 4
“tuberculosis.[55] Significantly, nanomolar concentrations of TMC207 were able to kill dormant pathogen by blocking ATP synthase activity at a higher efficacy than observed for replicating mycobacteria, despite ATP synthase being transcriptionally downre‐ gulated in latent M.”
BackgroundToxoplasma as a Model System for Apicomplexan Drug Discovery
Donald, R. G. K. (2007) · Elsevier eBooks · doi:10.1016/b978-012369542-0/50021-0 · Cited by 4
Microbial sequencing to improve individual and population health
Peacock, S. J., & Weinstock, G. M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0103-5 · Cited by 4
“subunit of ATP synthase was identified as the target of bedaquiline [8].”
From parasite genomes to one healthy world: Are we having fun yet?
Zarlenga, D. S., & Gasbarre, L. C. (2009) · Veterinary Parasitology · doi:10.1016/j.vetpar.2009.06.010 · Cited by 4
“Among the first applications of whole-genome and next generation sequencing to drug validation, was defining the mechanism of action of the new drug R207910 for treating Mycobacterium tuberculosis (Andries et al., 2005); the first tuberculosis-specific drug candidate developed in over 40 years.”
BackgroundAdvances in diagnosis and therapy of childhood tuberculosis
Woods, C. R. (2006) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2006.04.223 · Cited by 4
Chapter 5: Recent Developments in the Study of Pyrazinamide: An Update
Mitchison, D. A., & Zhang, Y. (2011) · Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · doi:10.1159/000324221 · Cited by 4
(2012) · Studies in natural products chemistry · doi:10.1016/b978-0-444-59530-0.00015-0 · Cited by 5
Boechat, N., & Pinheiro, L. C. S. (2012) · Revista Virtual de Química · doi:10.5935/1984-6835.20120020 · Cited by 4
New Chemical Entities Entering Phase III Trials in 2011
Notte, G. T. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00030-8 · Cited by 4
Cumming, B. M., Baig, Z., Addicott, K. W., Chen, D., & Steyn, A. J. C. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00932-21 · Cited by 4
“tuberculosis F1Fo ATP synthase and hence ATP production (106), in addition to modulating respiration (86) and metabolism (107, 108) CFZ Competes with menaquinone, a cofactor of theM.”
BackgroundHistoire et actualité du traitement de la lèpre
Reibel, F., Cambau, E., & Aubry, A. (2015) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2015.01.004 · Cited by 4
Self-citationToward a new era in sequencing
Ziebolz, B., & Droege, M. (2007) · Biotechnology annual review · doi:10.1016/s1387-2656(07)13001-5 · Cited by 4
The Next‐Generation Genome Sequencing: 454/Roche GS FLX
Du, L., & Egholm, M. (2008) · doi:10.1002/9783527625130.ch4 · Cited by 4
Mycobacterium tuberculosis: Drug Resistance and Genetic Mechanisms – Facts, Artifacts, and Fallacies
Böttger, E. C., & Springer, B. (2009) · doi:10.1002/9783527627905.ch5 · Cited by 4
Tuberculose : encore plus fort que la multirésistance
Blanc, F. –. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)72007-1 · Cited by 4
Illumina Genome Analyzer II System
Lakdawalla, A., & VanSteenhouse, H. C. (2008) · doi:10.1002/9783527625130.ch2 · Cited by 4
Repurposed kinase inhibitors and β-lactams as a novel therapy for antibiotic resistant bacteriaPreprint
Wlodarchak, N., Teachout, N., Procknow, R. R., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/199422 · Cited by 4
Nimmo, C., Ortiz, A. T., Pang, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.06.328799 · Cited by 4
A chemical-genetic map of the pathways controlling drug potency in Mycobacterium tuberculosisPreprint
Li, S., Poulton, N. C., Chang, J. S., Azadian, Z. A., DeJesus, M. A., Ruecker, N., Zimmerman, M. D., Eckartt, K. A., Bosch, B., Engelhart, C. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.27.469863 · Cited by 4
“, 1994) (Figure 93 1C), and bedaquiline (ATP synthase) (Andries et al., 2005) (Figure 1D) were among the most sensitized 94 hits in each respective screen.”
BackgroundDerendinger, B., Dippenaar, A., de Vos, M., et al. (2022) · medRxiv · doi:10.1101/2022.11.14.22282167 · Cited by 4
“Program (14-15090) and the University of Cape Town Human Research Ethics Committee 162”
BackgroundMethodLibreros-Zúñiga, G. A., Silva, C. D. S., Ferreira, R. S., et al. (2019) · PubMed · doi:10.1021/acsinfecdis.8b00244 · Cited by 3
Hassanien, A. E. E., Elsherbiny, G., Abdel-Fattah, G. M., et al. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11130-9 · Cited by 3
“Numerouspotentialrecentadvancementsinanti-TB agents [15] include nitroimidazopyrans [16], diarylquino-lines [17], and fluoroquiolnes (Moxifloxacin and Gati-floxacin) [18].”
Dennison, A. L., Singh, A., Marchlewski, T. A., Ghee, S. N., Gencel, K., Hammock, A. G., Liu, S., Wilson, S., Williams, A. P. L., Ward, K. T., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c06380 · Cited by 3
Wu, H., Pu, X., Wang, X., Liu, G., Ren, T., & Yang, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c11062 · Cited by 3
Mycobacterium avium : Diversity, Clinical Significance, Old and New Targeted Medicines
Nguyen, T. Q., Biet, F., Behr, M. A., & Kremer, L. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c01091 · Cited by 3
Mosallam, N., O’Neill, P. M., Lisauskaitė, M., Woodley, C. M., Ardrey, A., Jeffreys, L. N., Memelis, I., Almeida, D. V., Lee, J., Converse, P. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03274 · Cited by 3
Flores‐Valdez, M. A., & Chopra, S. (2009) · Microbial Drug Resistance · doi:10.1089/mdr.2009.0087 · Cited by 3
“In comparison, the resistance frequency for INH and RIF is *10 (7)–10 (8); thus, at the start of the multidrug therapy, there could be *1–1,000 bacteria already resistant to the drugs present in the population.(1) After the administration of these drugs, these resistant bacteria would be amplified, possibly leading to…”
A breakthrough in the treatment of multidrug-resistant tuberculosis
Pardeshi, V., Lokhande, T. N., Shelke, A. V., Tuse, T., Pawar, B., & Bonde, C. G. (2022) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ecdt.ecdt_24_22 · Cited by 3
Antimycobacterial Activity of Sida hermaphrodita (L.) Rusby (Malvaceae) Seed Extract
Lewtak, K., Czaplewska, P., Wydrych, J., Keller, R., Nowicka, A., Skrzypiec, K., & Fiołka, M. J. (2023) · Cells · doi:10.3390/cells12030397 · Cited by 4
Multi-Omics Approaches in Drug Discovery
Rakshit, G., Komal, K., Dagur, P., & Jayaprakash, V. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-1316-9_4 · Cited by 3
Structural and functional characterization of FabG4 from Mycolicibacterium smegmatis
Ran, X., Parikh, P., Abendroth, J. A., Arakaki, T. L., Clifton, M. C., Edwards, T. E., Lorimer, D. D., Mayclin, S. J., Staker, B. L., Myler, P. J., et al. (2024) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x2400356x · Cited by 3
Bhanwala, N., Sundaramoorthy, N. S., Gollapudi, S., et al. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03295-z · Cited by 3
“Speci fi cally, we varied the substituents at positions 2nd and 6th of the quinoline scaffold, as studied previously to be the most important position for its anti-TB activity [18, 19].”
Recent advances in inhibitor development and metabolic targeting in tuberculosis therapy
Patel, R. R., Vidyasagar, Singh, S. K., & Singh, M. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107515 · Cited by 4
Bai, Y.-F., Wang, L., Chen, Y., et al. (2011) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2011.08.033 · Cited by 3
3-Benzyl-6-methyl-2-sulfanylidene-2,3-dihydroquinazolin-4(1H)-one
Al‐Salahi, R. A., Al-Omar, M. A., El‐Subbagh, H. I., et al. (2012) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536812006009 · Cited by 3
First use of bedaquiline in a patient with XDR-TB in Singapore
Chua, A. P.-G., Hoo, G. S. R., Chee, C. B.-E., et al. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-210961 · Cited by 3
Sasi, B. S. A., Twinkle, A. R., & James, C. (2017) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2017.03.125 · Cited by 3
Moynihan, P. J., & Besra, G. S. (2017) · Microbiology · doi:10.1099/mic.0.000522 · Cited by 3
“M. tuberculosis F0F1 ATP synthase, for example, was identified in this way as the target for TMC207 [3].”
BackgroundInfluentialRedox‐guided small molecule antimycobacterials
Kulkarni, A., Sharma, A., & Chakrapani, H. (2018) · IUBMB Life · doi:10.1002/iub.1867 · Cited by 5
“The most recent addition to the arsenal—Bedaquiline—works well against drug-resistant strains (5).”
BackgroundExpedient phosgene-free synthesis of symmetrical diarylureas from carbamates
Elghamry, I., & Abdelsalam, M. (2019) · ARKIVOC · doi:10.24820/ark.5550190.p010.997 · Cited by 3
Drugs against Mycobacterium tuberculosis
Singh, R., Kumar, P., & Tahlan, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818480-6.00006-0 · Cited by 4
Potential implications of the use of Rapanea melanophloeos (L.) Mez against mycobacteria
Gibango, L., Oosthuizen, C. B., & Lall, N. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.06.003 · Cited by 3
Kumar, A., Prajapati, R., Kant, R., et al. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202000906 · Cited by 3
Hit movie reveals how a tuberculosis drug halts ATP synthesis
Mizrahi, V., & Barry, C. E. (2020) · Nature · doi:10.1038/d41586-020-03406-x · Cited by 3
Patel, H., Ahmad, I., Jadhav, H., et al. (2020) · Reviews and Advances in Chemistry · doi:10.1134/s2079978020030048 · Cited by 3
Arega, A. M., Dhal, A. K., Nayak, S., & Mahapatra, R. K. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05148-1 · Cited by 3
Roy, D., Thakare, R., Chopra, S., et al. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220823111812 · Cited by 3
Li, M., Yamada, Y., Rodríguez, G. M., Dick, T., & Go, M. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01970-22 · Cited by 4
Nandikolla, A., Khetmalis, Y. M., Sangeetha, G., et al. (2023) · New Journal of Chemistry · doi:10.1039/d3nj01907a · Cited by 3
Guo, K., Wang, Y., & Ma, C. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115658 · Cited by 3
Chakraborty, G., Ambily Nath, I. V., Sharma, M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2259486 · Cited by 3
“…have demonstrated that the Mtb c-ring mutations L59, E61, A63, F65, and I66 (corresponds to L63, E65, A67, F69, and I70 in M.phlei ) have a direct impact on the BDQ binding than any other mutant counterparts (Andries et al., 2005; Karmakar et al., 2019; Preiss et al., 2015; Rocchia et al., 2001).”
Microbial glycosylation of antitubercular agent chlorflavonin
Ren, J., & Zhan, J. (2023) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2023.09.005 · Cited by 3
Słabońska, J., Sappati, S., Marciniak, A., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00509 · Cited by 3
Huang, Y.-W., Yu, M.-C., Lin, C., et al. (2024) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2024.04.008 · Cited by 3
Jado, J. C., Dow, M. T., Carolino, K., Klie, A., Fonseca, G. J., Ideker, T. E., Carter, H. K., & Winzeler, E. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-63943-7 · Cited by 3
“Alternatively, there are also studies in which evolution has been used as a tool to discover targets and resistance genes for therapeutic purposes 7,64,84 .”
BackgroundMatar, I. K., Dong, Z., & Matta, C. F. (2024) · ChemMedChem · doi:10.1002/cmdc.202400303 · Cited by 4
Evolution of Small Molecule Inhibitors of Mycobacterium tuberculosis Menaquinone Biosynthesis
Sharma, P. N., Jiang, Q., Li, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03156 · Cited by 3
Inosine monophosphate overcomes the coexisting resistance of mcr-1 and blaNDM-1 in Escherichia coli
Zhao, L., Xu, J., Liu, S., Du, J., Jia, X., Wang, Z., Ge, L., Cui, K., Ga, Y., Li, X., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.043 · Cited by 3
“As a core molecule in cell metabolism, suffi-cient ATP is essential for maintaining bacterial proliferation; in contrast, excessive reduction in ATP can directly trigger cell death [46–49].”
Metadata
- Authors
- Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., & Jarlier, V.
- Affiliations
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
- Corresponding author
- Andries, Koen
- Lounis, Nacer
- Venue
- Science
- Published
- 2005-01-14
- Volume
- 307
- Issue
- 5707
- Pages
- 223-227
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2158658436
- Cited by
- 2,191
- References
- 13
- Citations by year
- 2026: 63 · 2025: 98 · 2024: 103 · 2023: 106 · 2022: 111 · 2021: 98 · 2020: 136 · 2019: 141 · 2018: 102 · 2017: 124 · 2016: 120 · 2015: 129 · 2014: 140 · 2013: 106 · 2012: 102
- FWCI
- 27.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- diarylquinolines, Mycobacterium tuberculosis, tuberculosis drug resistance, ATP synthase inhibition, proton pump, bactericidal activity, combination therapy, isoniazid
- MeSH terms
- Amino Acid Sequence, Animals, Antitubercular Agents, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Therapy, Combination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
